Novavax Inc (NVAX)

[TRUISM]

Novavax Coverage Initiated by Analysts at JPMorgan Chase & Co. (NVAX)
Posted by Masoud Bidgoli on Oct 7th, 2014 //

Click For mideasttime.com Link





JPMorgan Chase & Co. assumed coverage on shares of Novavax (NASDAQ:NVAX) in a research note issued on Tuesday, TheFlyOnTheWall.com reports. The firm set an “overweight” rating on the stock.

A number of other firms have also recently commented on NVAX. Analysts at Piper Jaffray raised their price target on shares of Novavax from $9.00 to $10.50 in a research note on Wednesday, September 24th. They now have an “overweight” rating on the stock. Separately, analysts at Wedbush initiated coverage on shares of Novavax in a research note on Thursday, September 18th.

They set an “outperform” rating and a $10.00 price target on the stock. Finally, analysts at Citigroup Inc. initiated coverage on shares of Novavax in a research note on Wednesday, August 13th. They set a “buy” rating and a $9.00 price target on the stock. Seven equities research analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and a consensus price target of $9.90.

In other Novavax news, SVP Gregory M. Glenn unloaded 16,809 shares of the stock in a transaction that occurred on Friday, September 26th. The stock was sold at an average price of $4.16, for a total transaction of $69,925.44. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Novavax (NASDAQ:NVAX) opened at 4.20 on Tuesday. Novavax has a one year low of $2.68 and a one year high of $6.95. The stock has a 50-day moving average of $4.52 and a 200-day moving average of $4.44. The company’s market cap is $1.000 billion.

Novavax (NASDAQ:NVAX) last announced its earnings results on Wednesday, August 6th. The company reported ($0.08) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.07) by $0.01. The company had revenue of $8.26 million for the quarter, compared to the consensus estimate of $8.74 million. During the same quarter in the prior year, the company posted ($0.08) earnings per share. The company’s quarterly revenue was up 134.0% on a year-over-year basis. Analysts expect that Novavax will post $-0.29 EPS for the current fiscal year.

Novavax, Inc (NASDAQ:NVAX) is a clinical stage biopharmaceutical company.





TRUTH